Postoperative Uterine Necrosis and Peritonitis Following Laparoscopic Radiofrequency Myoma Ablation

Lin, Emily; Sendukas, Emily; Kho, Kimberly A.

doi:10.1016/j.jmig.2022.06.006

Cited by 8 publications

(4 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…21 22 Though total adverse events are low (1.78%), a case report of postoperative necrosis and peritonitis in a treated fibroid of > 10 cm dimension has been described. 23 Serosal bowel injury and postoperative pelvic abscess due to ultrasound probe use were also noted in the pivotal HALT trial. The average length of stay is 10.7 hours with mean return to work after 4.3 days.…”

Section: Short- and Long-term Outcomesmentioning

confidence: 95%

“…24 In the pivotal HALT trial, menstrual blood loss reduction was measured via alkaline hematin. 23 This reduced within 3 months of treatment by 31.8% (95% confidence interval [CI]: À40.3% to À20.3%) and decreased to 38.3% (95% CI: À45.2% to À31.4%) at 12 months (p < 0.001). Similarly, within 3 months, the total mean fibroid volume reduced by 39.8% (95% CI: À44% to À35.6%) with continued decrease at 12 months to 45.1% (95% CI: À51.6% to À38.6%, p ¼ 0.001).…”

Section: Short-and Long-term Outcomesmentioning

confidence: 99%

See 1 more Smart Citation

Updates on the Surgical Approach to Fibroids: The Importance of Radiofrequency Ablation

Kwon,

Abu-Alnadi

2023

Semin intervent Radiol

View full text Add to dashboard Cite

Uterine fibroids are the most common benign neoplasm of the female pelvis and have a lifetime prevalence exceeding 80% among African American women and approaching 70% among Caucasian women. Approximately 50% of women with fibroids experience symptoms which can range from heavy menstrual bleeding and bulk-related symptoms such as pelvic pressure with bladder and bowel dysfunction to reproductive dysfunction (e.g., infertility or obstetric complications) and pain. The choice of treatment is primarily guided by the type of symptoms in the individual patient and whether they prefer to retain fertility. While hysterectomy provides definitive resolution of fibroid symptoms and remains the most common treatment option, this procedure is invasive with a long recovery window. Radiofrequency ablation (RFA) is now emerging as a uterine preserving and minimally invasive therapy for symptomatic fibroids. Since its introduction, growing evidence for safety and efficacy of RFA has been generated with low rates of complications. This review will discuss RFA for the management of symptomatic uterine fibroids with a special focus on technical approaches, short- and long-term outcomes including fertility outcomes.

show abstract

Section: Short- and Long-term Outcomesmentioning

confidence: 95%

Section: Short-and Long-term Outcomesmentioning

confidence: 99%

Updates on the Surgical Approach to Fibroids: The Importance of Radiofrequency Ablation

Kwon,

Abu-Alnadi

2023

Semin intervent Radiol

View full text Add to dashboard Cite

show abstract

“…15 A case report describes postoperative necrosis and peritonitis requiring hysterectomy after treatment of a 10×12-cm leiomyoma with laparoscopic RFA, possibly related to a large amount of residual necrotic tissue. 16 Several studies have demonstrated safe use of laparoscopic RFA for leiomyomas up to 10 cm despite the initial trial exclusion of leiomyomas larger than 7 cm. However, the described complication represents evidence for caution with RFA use in significantly large leiomyomas larger than 10 cm.…”

Section: Short-term Outcomesmentioning

confidence: 99%

Radiofrequency Ablation of Leiomyomas

Stewart

Greenberg

Kho

et al. 2023

Obstetrics &Amp; Gynecology

Self Cite

View full text Add to dashboard Cite

show abstract

“…Though a growing body of literature has demonstrated its clinical effectiveness [2][3][4][5][6] and short learning curve, 7 there remains a paucity of information regarding adverse events and device malfunctions encountered during RFA procedures. 8,9 We studied RFA device-related events reported to the FDA's Manufacturer and User Facility Device Experience (MAUDE) database to determine whether there are emerging devicerelated issues.…”

mentioning

confidence: 99%

Radiofrequency Ablation for Treatment of Leiomyomas

Young

Puma

Latham

et al. 2023

Obstetrics &Amp; Gynecology

Self Cite

View full text Add to dashboard Cite

Radiofrequency ablation (RFA) is a relatively novel, increasingly popular treatment option for leiomyomas. We studied medical device–related reports of leiomyoma RFA devices to determine whether there are emerging device-related issues. The Food and Drug Administration’s Manufacturer and User Facility Device Experience (MAUDE) database was queried from 2012 through November 2022. Sixty unique reports, including adverse events and device malfunctions, were analyzed for both laparoscopic and transcervical RFA devices. Forty-three injury reports were reviewed. The most common adverse event was infection. Of the injury cases, 34.9% required additional surgical intervention. Although the details of each event are limited, these reports highlight the importance of postmarket surveillance of new technologies and the necessity of improving the current system of implementation and monitoring.

show abstract

Postoperative Uterine Necrosis and Peritonitis Following Laparoscopic Radiofrequency Myoma Ablation

Cited by 8 publications

References 6 publications

Updates on the Surgical Approach to Fibroids: The Importance of Radiofrequency Ablation

Updates on the Surgical Approach to Fibroids: The Importance of Radiofrequency Ablation

Radiofrequency Ablation of Leiomyomas

Radiofrequency Ablation for Treatment of Leiomyomas

Contact Info

Product

Resources

About